Table 1.
Demographic and menopause characteristics of study subjects.
| Cycling | Natural menopause | Surgical menopause | Menopause from chemotherapy or radiation | |
|---|---|---|---|---|
| N (% total in table) | 326 (47.2) | 244 (35.4) | 65 (9.4)3 | 55 (8.0)4 |
| Age at last clinic visit, years (mean (SD)) | 40.0 (7·6) | 58.4 (7.1) | 56.9 (7.9) | 53.4 (8.6) |
| Age at first symptom, years (mean (SD)) | 29.2 (7.6) | 39.4 (9.8) | 37.1 (9.3) | 30.5 (10.5) |
| White (N (%)) | 290 (91.8) | 232 (95.1) | 61 (93.8) | 54 (98.2) |
| Hispanic (N (%)) | 19 (5.9) | 4 (1.6) | 1 (1.5) | 1 (1.8) |
| Disease category (CIS, RR, SP, PP, PR) (N (%)) | 23, 287, 9, 4, 3 (7, 88, 3, 1, 1) | 8, 179, 43, 12, 2 (3, 73, 18, 5, 1) | 1, 44, 17, 1, 2 (2, 68, 26, 2, 3) | 0, 17, 34, 4, 0 (0, 31, 62, 7, 0) |
| EDSS at last clinic visit (mean, (SD)) | 1.56 (1.57) | 2.77 (2.24) | 3.01 (2.30) | 4.88 (2.13) |
| Reported age at menopause, years (mean (SD)) | 49.2 (5.6) | 42.9 (8.0) | 42.7 (6.5) | |
| Ever-use systemic E or E+P HRT within 5 years of menopause (N (%))2 | 32 (15.0) | 17 (28.3) | 10 (19.2) |
CIS=clinically isolated syndrome, E=estrogen, HRT=hormone replacement therapy, P=progesterone, PP=primary progressive MS, PR=progressive relapsing MS, RR=relapsing remitting MS, SD=standard deviation, SP=secondary progressive MS
1. Perimenopausal women were excluded from this table (n=30); 4 post-menopausal women did not provide information on type of menopause so they were excluded from this table as well.
For this calculation, 31 natural menopause, 5 surgical menopause and 3 chemotherapy/radiation menopause subjects did not have sufficient data to assess the timing of HRT use.
Among the 46 women who underwent surgical menopause, 20 underwent bilateral oophorectomy only, 19 underwent bilateral oophorectomy and hysterectomy, 24 underwent hysterectomy only, and two underwent unilateral oophorectomy with final menstrual period at the time of the surgery.
Menopause resulted from chemotherapy in 51 subjects and from radiation in 4 subjects.